市場調查報告書
商品編碼
1136902
全球診斷導管市場-2022-2029Global Diagnostic Catheter Market - 2022-2029 |
※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。
全球診斷導管市場的增長受到全球心血管手術數量不斷增加、外科手術以及微創手術趨勢等因素的推動。
不斷湧現的新穎和創新技術進步正在推動市場增長。
與診斷導管相關的技術進步正在推動全球市場增長。例如,2021 年 6 月,雅培宣布它可以支持對機械循環支持設備不斷增長的需求,以充分治療晚期心力衰竭。
根據國家健康和營養檢查調查 (NHANES) 數據 (2020),估計有 620 萬美國 20 歲及以上成年人 (2.2%) 患有心力衰竭。超過 570 萬美國人患有心力衰竭,每年診斷出大約 915,000 例新病例。由於不健康的生活方式和環境變化,心力衰竭、心血管疾病和冠狀動脈疾病等慢性疾病的患病率在全球範圍內不斷增加。這些最新的產品發布和技術進步將能夠對抗這些疾病。例如,2022 年 4 月,富蘭克林醫療山宣布其經皮導管系統 UltraNav 已獲得美國食品和藥物管理局的批准。它通過經皮穿刺提供心血管導管的受控輸送。
主要關鍵參與者正在生產新穎和創新的產品,這些關鍵參與者正在進行各種管道和研究以推動市場增長。例如,2022 年 8 月,阿斯利康公佈了 DAPA-HF 和 DELIVER 的 3 期試驗分析的新結果,表明 Falixiga 與安慰劑相比在心力衰竭患者中的□□死亡率益處。
與診斷導管相關的副作用阻礙了市場增長。
然而,熟練醫務人員的短缺、嚴格的政府法規以及副作用的出現阻礙了市場的發展。其中,副作用的發生有望抑制市場。例如,中風、化學過敏和食道損傷在普通人群中很少見。
COVID-19 影響分析
與 Covid-19 傳播相關的封鎖和旅行限制給新的診斷導管製造商帶來了問題。由於 COVID-19 感染的傳播對主要經濟體產生了重大影響,診斷性導管插入藥物的生產受到了很大影響。
市場參與者正在改變他們的長期和短期增長戰略,利用研究市場和創造尖端產品來抗擊這一流行病。即使 COVID-19 對診斷導管行業造成影響,盡快制定業務運營的備用計劃也很重要。
您將可以訪問全球診斷導管市場報告中大約 40 多個市場數據表、45 多個數字和 200 頁(大約)。
Diagnostic Catheter Market was valued at US$ 4,292.31 million in 2021 and is estimated to reach US$ 6,628.54 million by 2029, growing at a CAGR of 7.04% during the forecast period (2022-2029).
A diagnostic catheter is a thin plastic tube inserted into the artery through a small incision on the skin. Once the catheter is guided to the area to be examined, a contrast material (radiopaque media or therapeutic agent) is injected through the tube and images or required information are captured using technological equipment such as (micro cameras, x-ray fluids, pressure monitors, etc.).
The global diagnostic catheter market growth is driven by factors, such as the increase in cardiovascular surgeries globally, surgical procedures, and an inclination towards minimally invasive surgeries.
The increasing number of novel, innovative technological advancements are driving the market growth.
The market is driven by the increasing technological advancements related to diagnostic catheters fuelling the market's growth globally. For instance, in Jun 2021, Abbott announced that the company could support the growing demand for mechanical circulatory support devices to treat advanced heart failure properly.
According to the National Health and Nutrition Examination Survey (NHANES) data (2020), an estimated 6.2 million American adults ≥20 years of age (2.2%) had heart failure. More than 5.7 million Americans suffer from heart failure, and approximately 915,000 new patients are diagnosed annually. The prevalence of chronic ailments like heart failure, cardiovascular disease, and coronary artery disease is increasing due to unhealthy lifestyles and changing environments worldwide. These latest product launches and technological advances will be able to combat these diseases. For instance, In Apr 2022, Franklin Medical Mountain announced it received approval for UltraNav, a transseptal catheter system, from the United States Food and Drug Administration. It will provide controlled delivery of cardiovascular catheters by the transseptal puncture.
Major key players are producing novel, innovative products and various pipelines and studies are being conducted by these key players to derive market growth. For instance, in Aug 2022, AstraZeneca presented its novel results from the analysis of phase III trials of DAPA-HF and DELIVER that shows the mortality benefit of Farxiga over placebo in heart failure patients.
The side effects associated with diagnostic catheters will hamper the market's growth.
However, the lack of skilled medical professionals, stringent government regulations, and the onset of side effects hamper the market. Among these, the onset of side effects is expected to restrain the market. For instance, stroke, chemical allergies, and esophageal injury are seen in less percentage of the total population.
COVID-19 Impact Analysis
Due to lockdowns and travel restrictions brought on by the spread of COVID-19, makers of novel diagnostic catheters experienced problems. Because the spread of COVID-19 infections badly impacted major economies, diagnostic catheter therapeutics production was greatly impacted.
Market participants are changing their long-term and short-term growth strategies by utilizing the research market and creating cutting-edge items to combat the pandemic. Even though COVID-19 harmed the diagnostic catheter industry, preparing and implementing backup plans as soon as possible for business operations is crucial.
The imaging diagnostic catheters segment is expected to grow at the fastest CAGR during the forecast period (2022-2029)
The imaging diagnostic has the largest market share in the forecast period. Electrophysiology mapping (EP) devices sub segment hold the largest market share as these catheter devices are often used to confirm the atrial fibrillation diagnosis and to decide its most suitable treatment. Due to its incorporated mapping capability, the usage of EP mapping catheters is increasing. The non-mapping electrophysiology catheters are less expensive than mapping ones as they do not provide the mapping. Various latest innovations are leading towards the growth of the market. For instance, in Jan 2022, Abbott announced that its cardiac mapping platform, Ensite X EP system with Omnipolar technology, got clearance from the U.S. FDA. This mapping system is developed to assist physicians in better treatment of cardiac arrhythmias. It provides the heart's detailed three-dimensional map as it's designed with the electrophysiologist's inputs.
The North American region holds the largest global diagnostic catheter market.
North America dominates the diagnostic catheter market and is expected to show a similar trend over the forecast period. The growth of North American diagnostic catheters can be attributed to the rising prevalence of heart failure cases and the surge in the geriatric population. Strong healthcare infrastructure and an increase in research and development expenditure are to blame for this supremacy. Furthermore, the rising prevalence of cardiovascular diseases in this region due to unhealthy lifestyles and diets has propelled diagnostic catheter demand in the market.
According to the American Heart Association report 2020, approximately 790,000 people in the U.S. have heart attacks yearly. The rising number of people suffering from cardiovascular diseases and growing technological advancements and mergers or acquisitions by key players boost the demand for diagnostic catheter treatment in this region. For instance, in Jun 2021, Abiomed announced its acquisition of a precardiac catheter developer that provides less invasive options for treating patients with acute decompensated heart failure.
The diagnostic catheter market is highly competitive with local and global companies. Some key players contributing to the market's growth are B. Braun Melsungen AG, Abbott, Medtronic, Boston Scientific, Infiniti Medical, Merit Medical, Osypka AG, Terumo Corporation, and Royal Philips, among others. The major players are adopting several growth strategies, such as product launches, acquisitions, and collaborations, contributing to the growth of the diagnostic catheter market globally. For instance, in Feb 2022, Interrad Medical, a private company of medical devices, and Eloquest Healthcare announced their strategic partnership to expand SecurAcath sales in the U.S.
B. Braun Melsungen AG.
B. Braun is a company that manufactures medical and pharmaceuticals device. Headquartered in Melsungen, Germany and established in 1839. They provide services in around 60 countries and employ around 63,000 people. They have around 5,000 varieties of healthcare products.
Angiodyn diagnostic catheters: Angiodyn diagnostic catheters are used for coronary angiographies. For 1:1 force transmission, it contains a symmetrical braided shaft.
In Jul 2022, B. Braun Medical Inc., a developer of infusion therapy, launched its one-time blood control Introcan safety 2 IV catheter. It is developed for safe IV access.
The global diagnostic catheter market report would provide access to approximately 40+ market data tables, 45+ figures, and 200 (approximate) pages.
LIST NOT EXHAUSTIVE